Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics

The year of 2005 was a watershed in the history of poly(ADP-ribose) polymerase (PARP) inhibitors due to the important findings of selective killing in BRCA-deficient cancers by PARP inhibition. The findings made PARP inhibition one of the most promising new therapeutic approaches to cancers, especia...

Full description

Saved in:
Bibliographic Details
Published in:Acta pharmacologica Sinica 2010-09, Vol.31 (9), p.1172-1180
Main Authors: He, Jin-xue, Yang, Chun-hao, Miao, Ze-hong
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Biomedical and Life Sciences
Biomedicine
Clinical Trials as Topic
Enzyme Inhibitors - pharmacology
Enzyme Inhibitors - therapeutic use
Humans
Immunology
Internal Medicine
Medical Microbiology
Neoplasms - drug therapy
Neoplasms - enzymology
Pharmacology/Toxicology
Poly(ADP-ribose) Polymerase Inhibitors
Poly(ADP-ribose) Polymerases - metabolism
Review
Vaccine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The year of 2005 was a watershed in the history of poly(ADP-ribose) polymerase (PARP) inhibitors due to the important findings of selective killing in BRCA-deficient cancers by PARP inhibition. The findings made PARP inhibition one of the most promising new therapeutic approaches to cancers, especially to those with specific defects. With AZD2281 and BSI-201 entering phase III clinical trials, the final application of PARP inhibitors in clinic would come true soon. This current paper will review the major advances in targeting PARP for cancer therapy and discuss the existing questions, the answers to which may influence the future of PARP inhibitors as cancer therapeutics.
ISSN:1671-4083
1745-7254
DOI:10.1038/aps.2010.103